



Contents lists available at ScienceDirect

Advanced Drug Delivery Reviews

journal homepage: www.elsevier.com/locate/addr

The mesmiRizing complexity of microRNAs for striated muscle tissue engineering[☆]

Mattia Quattrocelli^{a,c}, Maurilio Sampaolesi^{a,b,c,*}

^a Translational Cardiology Lab, Embryo and Stem Cell Biology Unit, Dept of Development and Regeneration, KU Leuven, Belgium

^b Division of Human Anatomy, Dept of Public Health, Experimental and Forensic Medicine, University of Pavia, Italy

^c Interuniversity Institute of Myology (IIM), Italy

ARTICLE INFO

Available online xxxx

Keywords:

microRNAs
Cardiac muscle
Skeletal muscle
Tissue engineering
Regenerative medicine
Exosomes
Circulating microRNAs

Chemical compounds studied in this article:

Locked adenosine
Locked cytosine
Locked guanosine
Locked uracyl
Polyethylene glycol
Fibrinogen
Collagen
Phenylephrine
Bromo-deoxy-uridine

ABSTRACT

microRNAs (miRs) are small non-protein-coding RNAs, able to post-transcriptionally regulate many genes and exert pleiotropic effects. Alteration of miR levels in tissues and in the circulation has been associated with various pathological and regenerative conditions. In this regard, tissue engineering of cardiac and skeletal muscles is a fascinating context for harnessing the complexity of miR-based circuitries and signals. In this review, we will focus on miR-driven regulation of cardiac and skeletal myogenic routes in homeostatic and challenging states. Furthermore, we will survey the intriguing perspective of exosomal and circulating miRs as novel paracrine players, potentially useful for current and future approaches of regenerative medicine for the striated muscles.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

1. Introduction	0
2. Biogenesis of miRs	0

Abbreviations: ACS, acute coronary syndrome; Ago-2, Argonaute 2; Akt, protein kinase B; AMI, acute myocardial infarction; anti-miR, antagomiRs against microRNA; Bcl-2, B cell leukemia/lymphoma 2; CAD, coronary artery disease; Camk-II γ , calcium/calmodulin-dependent protein kinase II gamma; CDC, cardiosphere-derived cell; Cdc-25a, cell division cycle 25A; circ-miR, circulating microRNA; cFos, cellular FBJ osteosarcoma oncogene; cJun, cellular jun proto-oncogene; CK, creatine kinase; CPC, cardiac progenitor cell; cTnI, cardiac troponin-I; Cx-43, connexin 43; Cypd, peptidylprolyl isomerase D; Dgcr-8, DiGeorge Syndrome Chromosome Region 8; Ezh-2, enhancer of zeste 2 polycomb repressive complex 2 subunit; FoxO-1a, forkhead box O1 a; Gata-4, GATA binding protein 4; Gw-182, Gw bodies protein (trinucleotide repeat containing 6A, Trc-6a); Hand-2, heart and neural crest derivatives expressed transcript 2; Hdac-4, histone deacetylase 4; HDL, high-density lipoproteins; Hif-1, hypoxia inducible factor 1; HoxA-11, homeobox A11; Hsp-60/70, heat-shock protein 60/70; Ip3r-III, inositol 1,4,5-trisphosphate receptor, type 3; Jnk, c-Jun N-terminal kinase; LNA, locked nucleic acid; Maml1, mastermind-like factor 1; MD, muscular dystrophies; Mecp-2, methyl CpG binding protein 2; Mef-2, myocyte enhancer factor 2; miR, microRNA; Mlk-3, mixed lineage kinase 3 (mitogen-activated protein kinase 11, Map3k-11); Murf-1, tripartite motif containing 63, E3 ubiquitin protein ligase; Myh/MyHC, myosin heavy chain; MyoD, myoblast determination protein; myomiR, myogenic microRNA; Ncx-1, solute carrier family 8 (sodium/calcium exchanger), member 1; Nkx2-5, NK2 homeobox 5; nt, nucleotide; Pax-3, paired box 3; Pdcd-4, programmed cell death 4; Pdlim-5, PDZ and LIM domain 5; pre-miR, precursor of microRNA; pri-miR, primary transcript of microRNA; Pten, phosphatase and tensin homolog; Pur- β , purine rich element binding protein β ; RISC, RNA-induced silencing complex; Rybp, RING1 and YY1 binding protein; Sca-1, stem cell antigen 1; Sdn-1/3, small RNA degrading nuclease 1/3; Shh, sonic hedgehog homolog; Sirt-1, sirtuin 1; Sorbs-2, sorbin and SH3 domain containing 2; Sox-6, SRY (sex determining region Y)-box 6; Sp-3, Sp3 transcription factor; Spred-1, sprouty-related EVH1 domain containing 1; Srf, serum response factor; Tbrp, TAR element RNA binding protein; Tgf β 3r-III, transforming growth factor beta receptor 3; Thrap-1, thyroid hormone receptor associated protein 1 (mediator complex subunit 13, Med-13); UTR, untranslated region; Vcam-1, vascular cell adhesion molecule 1; Vegf, vascular endothelial growth factor; Wnt, wingless-type MMTV integration site family; Xrn-2, 5'-3' exoribonuclease 2; Yy-1, YY1 transcription factor.

[☆] This review is part of the *Advanced Drug Delivery Reviews* theme issue on "MicroRNAs in tissue engineering and regenerative medicine".

* Corresponding author at: Translational Cardiology Lab, Dept of Development and Regeneration, KU Leuven, Herestraat 49-O&N4-bus 814, 3000 Leuven, Belgium.

E-mail address: maurilio.sampaolesi@med.kuleuven.be (M. Sampaolesi).

<http://dx.doi.org/10.1016/j.addr.2015.04.011>

0169-409X/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: M. Quattrocelli, M. Sampaolesi, The mesmiRizing complexity of microRNAs for striated muscle tissue engineering, *Adv. Drug Deliv. Rev.* (2015), <http://dx.doi.org/10.1016/j.addr.2015.04.011>

2.1.	Modulation of miRs	0
2.2.	Vesicular and non-vesicular trafficking of miRs	0
2.3.	Artificial tools to regulate miRs.	0
3.	Tissue engineering for striated muscles: room for miRs?	0
3.1.	Cardiac myogenesis and miRs	0
3.2.	MiRroring cardiac muscle diseases	0
3.3.	MiRs involved in heart failure	0
3.4.	Skeletal myogenesis and miRs	0
3.5.	MiRroring skeletal muscle diseases and fate switch	0
3.6.	MiRs, not miRacles: hints from and for regenerative medicine.	0
4.	Exosomal and circulating miRs in striated muscle regulation.	0
4.1.	Exosomes: a novel route of miR-based signals for cardiac muscle regulation	0
4.2.	Exosome-borne miRs for skeletal myogenesis regulation	0
4.3.	Circ-miRs: biomarkers and/or effectors in the context of cardiac damage?	0
4.4.	Circ-miRs in the context of skeletal muscle damage and physical exercise	0
5.	Future perspectives and conclusions	0
	Acknowledgments	0
	References.	0

1. Introduction

Striated muscles constitute approximately 40% of our body mass and are responsible for constant blood pumping, i.e. the cardiac muscle, and for posture and movements, i.e. the skeletal muscles. Several diseases chronically affect both cardiac and skeletal muscles, including muscular dystrophies (MDs) [1], cancer cachexia [2] and metabolic disorders [3]. At present, regenerative treatments are not yet available for the clinical care of striated muscle disorders, in spite of increasing demand and global burden [4]. Therefore, the field would benefit from a comprehensive understanding of cellular and molecular mechanisms governing generation and regeneration of both muscle types.

Over the last years, the static notion of post-mitotic tissues is under continuous re-shaping for striated muscles. Many findings have disclosed the possibility of (re)generating adult myocytes by means of stem cells or progenitors with different origins and potency [5]. Although the relevance for steady and pathological states is still fiercely debated [6,7], it is noteworthy that the study of (re)generation mechanisms has fueled a deeper venture into the complexity of muscle formation.

In this context, the post-transcriptional control exerted by microRNAs (miRs) constitutes one of the most remarkable layers of complexity [8]. MiR-gene feedback circuitries finely orchestrate cell-based engineering for striated muscle repair [9]. Also, it has recently become evident that miRs can be released in the circulation, probably cross-signaling on both short-range and long-range [10]. Thus, this review will focus on the miR-mediated complex regulation of myogenic routes in cardiac and skeletal muscles. In addition, it will report on the intriguing perspective of vesicular and non-vesicular circulating miRs (circ-miRs) with respect to challenging conditions of striated muscles.

2. Biogenesis of miRs

MiRs are conserved, ~22 nt-long, non protein-coding RNA molecules regulating gene expression at post-transcriptional stage. MiR-based gene regulation is intrinsically complex, considering that one transcript is targetable by different miRs and one miR can target different transcripts [11]. Currently, 1920 murine and 2603 human mature miR entries are reported in the miRbase sequence repository (miRbase.org; March 2015). MiR-encoding genes are present in the genome as intergenic clusters or individual transcriptional units. In both cases, their expression is under the control of promoters and enhancers with similar characteristics and regulation to those for protein-coding genes [12]. Several miRs, however, are embedded in the intronic sequences of other genes (miRtrons) and are then co-transcribed accordingly with the encompassing genes [13]. Following the canonical pathway, miR genes are generally transcribed by RNA polymerase II into primary transcripts of several hundred nucleotides (pri-miRs),

bearing secondary hairpin structures and undergoing 5' capping and 3' polyadenylation [14]. In few cases, miR genes are transcribed by RNA polymerase III [15]. While still inside the nucleus, the microprocessor complex, formed by the RNase-III Drosha and its co-factor Dgcr-8, cleaves the pri-miRs into ~70 nt-long precursor molecules (pre-miRs) [16]. Exportin-5, a Ran-GTP-dependent nuclear export protein, shuttles the pre-miRs into the cytosol [17]. Once in the cytosol, pre-miRs are further cleaved in ~22 nt-long double-stranded molecules by a complex that includes another RNase-III, Dicer, in combination with its RNA-binding cofactor, Tbrp [18]. After Dicer-mediated maturation, miRs are loaded on the RNA-induced silencing complex (RISC) as single strands. Mature miR duplexes are in fact separated in guide and passenger strands. The guide strand (*miR*) usually presents the weakest base pair at 5' and is preferentially loaded on the RISC complex, whereas the complementary passenger strand (*miR**) is preferentially degraded [19,20]. The RISC complex includes Argonaute proteins, such as Ago-2, and targets the *miR* to its messenger RNA (mRNA) targets. Also, Ago-2-binding protein, Gw-182, shuttles the miR-loaded, active RISC complex to discrete foci in the cytoplasm, called processing bodies (P-bodies), where several enzymes are available for mRNA decapping, deadenylation and degradation [21]. Although the exact mechanisms are still unclear, it seems that miRs generally recognize the 3' untranslated region (3'-UTR) of target mRNAs. According to the binding complementarity of the seed sequence (generally comprised between nt1 and nt9 at miR 5' end), miRs repress gene expression by targeting the mRNA for degradation (complete match) or by mediating translation inhibition (incomplete match). The latter is achieved through various mechanisms, including RISC-mediated destabilization of ribosomal assembly or translation continuation [22] (Fig. 1).

Non-canonical processing of miR transcripts, typical for miRtrons, relies on direct processing of the pre-miRs during intron splicing of the harboring gene mRNA. Other microprocessor-independent sources of pre-miRs encompass small nucleolar RNAs (snoRNAs), transfer RNA precursors (tRNAs) and short hairpin RNAs (shRNAs) [23].

2.1. Modulation of miRs

Many factors regulate miR biogenesis and hence affect downstream miR-mediated gene repression. RNA editing of pri-miRs or pre-miRs by deaminases [24], or through 3' uridylation, can influence Drosha- or Dicer-dependent processing steps. Also, abundance of Ago-2 or agonist proteins directly affects RISC activity levels. Another important aspect of intrinsic miR regulation, albeit still rather obscure, consists of turnover and degradation. After mRNA targeting and in the presence of still unknown signals, the *miR* guide strand is released and degraded. The turnover process of miRs still remains largely unknown. Average half-life of miRs has been estimated to ~119 h [25] and exoribonucleases,




Fig. 1. Biogenesis and trafficking of miRNAs. Once processed by microprocessor and Dicer complexes, miRNAs are loaded on the RISC complex, or are shuttled to exosomes or non-vesicular carriers for paracrine signaling, or shed into the circulation. MiRNAs are modulated through miR-mimics, antagomiRs and miRNAs that are shuttled by exosomes, protein- and HDL-carriers.

such as Xrn-2 and Sdn-1/3, take part in the process [26]. However, more systematic studies are needed to shed light on the selective mechanisms regulating miR turnover.

2.2. Vesicular and non-vesicular trafficking of miRNAs

Besides operating intracellularly, miRNAs can be released from the producing cells in the surrounding areas or in the circulation. Intriguingly, circulating miRNAs (circ-miRNAs) are traceable in plasma or serum and appear resistant to harsh conditions such as RNase activity, pH changes, boiling, freeze-thawing and storage at room temperature [27]. Carriers or membranous vesicles generally protect the circ-miRNAs in the bloodstream. Non-vesicle carriers encompass protein complexes, including Ago-2 and Nucleophosmine-1, and lipoprotein complexes, such as high-density lipoproteins (HDLs) [28]. Among the vesicle-based carriers, exosomes are emerging as important regulators of long-range miR shuttling [29]. Exosomes are small vesicles (40–100 nm diameter) that enclose their cargo with a lipidic bi-layer and are generated from intracellular multivesicular bodies [30]. Exosomes mature through a still unknown process, most likely at the interface with the Golgi reticulum, and then shed from the plasma membrane. Exosomes typically carry heat-shock proteins Hsp-60/70 in the lumen, and present tetraspanins, such as CD9/63/81, and tissue-specific membrane proteins on the surface [31]. At present, the relative abundance of vesicular or carrier-based formulations for circ-miRNAs in the bloodstream is still debated. Some reports suggest that the majority of circ-miRNAs are exosome-borne [32], whereas others suggest that circ-miRNAs are predominantly vesicle-free and carried in protein- [33] or lipoprotein-based complexes [34]. These discrepancies are probably due to still different and rather incomparable methodologies of investigation. However, following the notion of exosomes as miR carriers, a novel

layer of miR-based cross-communication emerges on top of the conventional intracellular regulations. Notwithstanding the lack of details concerning putative receptors and intracellular processing, it has been in fact reported that pre- or mature miRNAs are delivered to other cells [35], where they exert their specific regulation (Fig. 1).

2.3. Artificial tools to regulate miRNAs

Oligonucleotides, i.e. miR-mimics and antagomiRs, can enhance or repress endogenous miRNAs, respectively. MiR-mimics are artificial oligonucleotides that are similar in sequence and possibly in secondary structure to target pre-miRNAs. Once processed by the Dicer complex, miR-mimics load the RISC complex with the query mature miR [36]. MiR-mimics are deliverable *in vivo* through lipid-based preparations, which can however lead to unspecific uptake. Uptake specificity and transduction efficiency are increased with viral vector formulations, yet the issues of biodistribution and genome integration remain [37]. AntagomiRs are modified antisense oligonucleotides, competing with the endogenous miR for matching the target sequences. Also, antagomiRs can interfere with pri-miR biogenesis, nuclear export, pre-miR maturation and RISC loading. AntagomiRs are chemically enhanced with 2'-O-methyl, 2'-O-methoxyethyl or locked nucleic acid (LNA) nucleotides, in order to improve stability and hence duration of the inhibitory effect. AntagomiRs are deliverable in physiological-grade solutions, liposome- or nanoparticle-based formulations, or as cholesterol-conjugated oligonucleotides [38]. Noteworthy, an antagomiR has successfully passed a phase-II clinical trial, in which the interaction between hepatitis virus C and liver-expressed miR-122 was targeted. In this clinical study, patients received 5 weekly subcutaneous injections of the LNA-based antagomiR in concentrations ranging from 3 to 7 mg per body weight kg. Beneficial effects on the viral RNA load appeared dose-dependent

during 14 weeks of follow-up after treatment, without apparent dose-limiting adverse effects [39].

Another experimental tool of miR inhibition is the sponge, which is an artificially overexpressed gene carrying multiple miR-binding sites in tandem in its expanded 3'-UTR. Interestingly, sponges are particularly useful as they can inhibit up to a whole miR family with similar seed sequences [40]. Despite being highly variable in uptake and modulation efficiency, miR-mimics and antagomiRs/sponges represent attractive candidates to timely manipulate determined miRs during the formation of cardiac and skeletal muscle both in vitro and in vivo, at least in experimental and translational setups (Fig. 1).

3. Tissue engineering for striated muscles: room for miRs?

Striated muscle injury and degeneration account for significant fractions of adult mortality and disease burden worldwide. A notable example thereof is the ischemic heart disease, which constituted the first cause of both mortality and burden over the last decade (WHO Global Health Observatory, statistics related to 2000–2012). In addition, genetically inherited chronic myopathies still cause a conspicuous, yet unmet need for muscle tissue regeneration. In fact, the most severe form of MD, the Duchenne MD, afflicts approximately 1 in 3000 young males. Importantly, most MD forms feature chronic degeneration in both striated muscle compartments, i.e. heart and skeletal muscles. Therefore, the need for regenerative strategies for both muscle types is still highly compelling.

At present, in order to reach this ambitious goal, several fields are promisingly explored, including tissue engineering and stem cell-based treatments.

Tissue engineering aims at supporting functional regeneration of damaged striated muscles by means of generally three-dimensional implants that combine biocompatible scaffolds with bioactive molecules and/or stem cells [41,42]. Noteworthy for improving cardiac functionality is the application of cell sheets or tissue slices on the pericardium of damaged hearts. Myoblast cell sheets of ~100 µm thickness have been applied on the left ventricle of hamsters with dilated cardiomyopathy, resulting in maintenance of pre-operative values of fractional shortening [43]. Furthermore, cardiac slices obtained from adult or neonatal murine hearts have also shown promising results. Indeed, application of 200/400 µm-thick cardiac slices on the left ventricle of murine infarcted hearts resulted in improved ejection fraction at one month post-transplantation [44]. In both approaches, host-driven revascularization of the implant supports the hypothesis that paracrine signals play a major role in the functional amelioration. However, the implant-host cross exchange of resident progenitor cells and their fate

regulation thereafter still remain largely unaddressed. In this regard, it has been recently reported that an acellular matrix scaffold from porcine urinary bladder extensively mobilized and recruited perivascular progenitors in injured skeletal muscles of animal models and human patients. The colonized scaffold then counteracted the volumetric loss of skeletal muscle with novel functional fibers [45]. Albeit encouraging, it is still unknown whether such approach can cope with the major challenges of the upscaling and the hostile environment of chronically myopathic muscles.

Tissue engineering for striated muscle repair often entwines with stem cell-based treatments. In principle, transplantation of stem cells aims at providing the degenerating muscle tissue with progenitors able to engraft, to reconstitute genetically suitable myocytes and to restore, at least partially, the functionality. Main examples in such context are cardiac stem cells for the heart and satellite cells for the skeletal muscles. Cardiac stem cells, identified as c-Kit⁺ resident progenitors, are clonally expandable and induce functional regeneration of ischemic myocardium in animal models [46]. Moreover, autologous c-Kit⁺ cells have shown safety and partial efficacy outcome in a phase-I, randomized clinical trial [47,48]. In the skeletal muscle, satellite cells reside as quiescent cells under the basal lamina and, in case of injury, proliferate and potently regenerate damaged fibers [49]. However, satellite cells present a poor migratory potential when injected in the circulation, therefore blunting their clinical translation at present. Although intrinsically less committed, mesoangioblasts, i.e. resident myogenic pericytes, appear a translational alternative for skeletal muscle repair. Mesoangioblasts present, indeed, a high migration ability and have been shown as promising candidates in small and large animal models of MD [50,51]. Also, HLA-matched mesoangioblasts are currently under phase-I clinical study in MD patients (EudraCT #2011-000176-33). Recently, encouraging results for skeletal muscle engineering have been obtained through implantation of mesoangioblasts embedded in a polyethylene glycol–fibrinogen hydrogel. The implant was able to mature into artificial, functional skeletal muscle fibers in mice. Importantly, the cells were engineered to overexpress placental-derived growth factor, and the implant was successful with both murine and human mesoangioblasts [52]. With regard to the heart, myogenic mesoangioblasts [53] or pericytes [54] have been recently isolated also from the cardiac muscle, although their bench-to bedside progression appears slower as compared to aforementioned cell systems.

Lastly, it is important to mention the growing interest around pluripotent stem cells, both embryonic and induced, for striated muscle (re)generation. Diverse approaches of differentiation and progenitor cell sorting are currently available in literature [55,56], also in combination with genetic engineering [57] or epigenetically biased systems [58].

Table 1
MiR manipulation strategies relevant for cardiac muscle repair/protection.

miR	Target	Means of manipulation	Effects	Ref
miR-1/-133	Murine embryonic stem cells	Lentiviral transduction	cardiomyogenic potential	[66]
miR-1	Rat neonatal cardiomyocytes/murine adult heart	Adenoviral transduction	cardiac hypertrophic remodeling	[67]
miR-499	Human CPCs	Lentiviral transduction	cardiomyogenic potential	[70]
miR-1/-499	Human fetal cardiomyocyte progenitors	miR-mimic transfection	cardiomyogenic potential	[71]
miR-1/-499	Human embryonic stem cells	Lentiviral transduction	cardiomyogenic potential	[72]
miR-1/-133a/-208a/-499	Murine cardiac fibroblasts	miR-mimic transfection	cardiomyogenic conversion	[74]
miR-499	Rat bone marrow mesenchymal stem cells	Lentiviral transduction	cardiomyogenic conversion	[75]
miR-208a	Rat adult heart (hypertension-induced hypertrophy)	AntagomiR systemic delivery	cardiac hypertrophic remodeling	[76]
miR-21/-129/-212	Rat neonatal cardiomyocytes	miR-mimic transfection	cardiac hypertrophic remodeling	[80]
miR-21	Rat adult heart (acute injury)	Intracardiac adenoviral delivery	cardioprotection	[81]
miR-138	Rat CPCs	miR-mimic transfection	survival	[88]
miR-199a/-590	Rat/murine neonatal heart	miR-mimic transfection/AAV systemic delivery	cardiomyocyte proliferation	[90]
miR-15 family	Murine adult heart (acute injury)	AntagomiR systemic delivery	cardioprotection	[94]
miR-24	Rat cardiomyocytes (ischemia-like conditions)	miR-mimic transfection	survival (in vitro)	[95]
miR-21/-24/-221	Murine CPCs	Lentiviral transduction	survival (in vivo)	[96]
miR-22	Rat neonatal cardiomyocytes	miR-mimic transfection	cardiac hypertrophic remodeling	[101]
miR-34a	Human bone marrow mesenchymal stem cells	AntagomiR transfection	survival (in vivo)	[102]

The table concisely reports several experiments, and the related effects, of miR manipulation in cardiac cells or in the myocardium, with potential relevance to cardiac regeneration strategies.

Although a comprehensive dissertation on these cell systems would defeat the purpose of this review, it is of note for this work to highlight the theoretical potential of pluripotent cells to give rise to different striated muscle progenies [59]. However, issues such as myogenic efficiency and appropriate lineage commitment still currently hamper this potential, particularly for in vivo applications [60].

It is thus imperative for present and future strategies of striated muscle tissue engineering to potentially overcome the hurdles imposed by myogenic fate efficiency, topic survival rate and adverse signals from the diseased niche. MiRs are emerging as key players in all three aspects and, particularly, as tunable modulators of the myogenic program and the adaptability of both exogenous and resident stem cells [11]. However, factual progress in miR-based strategies still relies on unraveling the complexity of miRs in normal and pathologic contexts of myogenesis. This review will therefore focus on the role of miRs in experimental and translational settings of striated muscle de-/regeneration, and on novel insights from the largely unexplored field of circulating miRs.

3.1. Cardiac myogenesis and miRs

Diverse miRs finely modulate cardiac myogenesis (Table 1). The paramount role of miRs during cardiac muscle generation was firstly highlighted by the severe cardiac defects that, together with other major developmental aberrations, induced fetal lethality in *Dicer-null* mice [61]. The most abundant and investigated miRs involved in cardiac myogenesis are *miR-1*, *miR-133*, *miR-208*, and *miR-499*, members of the

“myomiR” group [62]. These miRs have complex pleiotropic effects on many aspects of cardiac myogenesis and muscle homeostasis (Fig. 2).

During cardiac development and maturation, *miR-1* and *miR-133* exert entwined spatiotemporal effects on expansion and terminal differentiation of cardiac progenitor cells (CPCs). Excess of *miR-1* limits the expansion of cardiac progenitors by repressing *Hand-2*, while *miR-1*-lacking murine embryos die at E10.5 because of severe cardiac malformations [63]. *MiR-133a* is fundamental for cardiac development and CPC proliferation by targeting *Cyclin-D2* and *Srf* in a negative feedback control [64,65]. Importantly, *miR-1* and *miR-133a/b* have also been shown to enhance the differentiation of pluripotent cells towards the mesodermal lineage. This has been assessed in murine embryonic stem cells transduced with a lentiviral vector that induced expression of both miRs at levels comparable to the endogenous miRs in the murine heart. The resulting increase of cardiomyogenic differentiation was due to two parallel mechanisms. *MiR-1* translationally repressed the Notch ligand *Dll-1*, while *miR-133* increased the proliferation of CPCs [66]. Therefore, sustained levels of *miR-1*/*miR-133* appear beneficial to the myogenic differentiation, albeit their modulation must be timely appropriate and stage-specific. Also, *miR-1* is downregulated in the diseased heart and adenoviral-mediated overexpression of *miR-1* (up to 5 fold endogenous levels) conversely attenuated hypertrophic remodeling. This evidence was gathered in rat neonatal cardiomyocytes and in adult murine hearts, where *miR-1* represses *Calmodulin* and *Mef-2a*. *MiR-1*-mediated effects were accordingly reverted in vitro in the presence of 1 pmol cholesterol-linked *anti-miR-1* [67]. Interestingly, the mature forms of *miR-1* and *miR-133a* are encoded from two




Fig. 2. Complexity of miR-based regulations in cardiac myogenesis. This diagram depicts a fraction of the miR pathways commented on this review, to synthesize the information regarding progenitor commitment and cardiomyocyte damage response. Genes are pseudocolored according to their function (legend), whereas miRs are pseudocolored according to the cognate process (arrows and squares). The same miRs can have different colors in accordance with the different contexts in which they are depicted. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

conserved bicistronic loci, *miR-1-1/miR-133a-2* on chromosome 2 and *miR-1-2/miR-133a-1* on chromosome 18 [68]. *Srf* and *Mef-2* transcription factors, both MADS-box transcription factors regulating cardiomyogenic regeneration, activate both miRs by recognizing specific enhancers [69].

Another important regulator of CPC maturation is *miR-499*. In human CPCs, lentiviral-mediated overexpression of *miR-499* by ~4000 fold endogenous levels depleted ~75% protein levels of targets *Sox6* and *Rod1*, enhancing the cardiomyogenic progression. Transduced, *miR-499*-overexpressing CPCs presented superior regenerative potential in vivo, once injected in infarcted hearts [70]. Moreover, particularly in combination with *miR-1*, *miR-499* was reported as direct regulator of cardiomyogenic differentiation. Transfection of up to 100 nmol synthetic *pre-miR-1/-499* in human fetal cardiomyocyte progenitors resulted in dose-dependent increase of differentiation efficiency at 12 days post-treatment [71]. Furthermore, overexpression of *miR-1/-499* precursors by lentiviral transduction in human embryonic stem cells increased target miR levels by ~30 fold and ~130 fold, respectively, across the embryoid body stage and ameliorated in vitro cardiomyogenesis [72]. Remarkably, *miR-499* has been implicated in junction-dependent miR trafficking, called “miRcrine mechanism”, between cardiomyocytes and regenerating CPCs, both in vitro and in vivo [73]. In addition, together with the other myomiRs, *miR-499* improves the direct conversion of cardiac fibroblasts into cardiomyocytes. Transfection of 50 nmol miR-mimics of *miR-1/-133a/-208a/-499* in murine cardiac fibroblasts was sufficient to exert significant changes on early cardiomyogenic markers at 3 days post-treatment. Analogous effects were obtained on mature differentiation markers at 7 days post-transfection. Accordingly, this defined miR signature is amenable also for conversion of endogenous fibroblasts in vivo. Indeed, direct intramyocardial injection of 2×10^6 lentiviral units at two sites downstream of the coronary artery ligation induced resident fibroblasts to convert to cardiac cells and to contribute to regenerated myocardium. In this study, the lentiviral vectors bore the miR/reporter cassette under a promoter prominently active in fibroblasts but not in other cardiac cells, strongly suggesting that the cardiomyogenic conversion was fibroblast-restricted [74]. Noteworthy, *miR-499* appeared sufficient to stimulate the expression of cardiac factors, e.g. *Nkx2-5*, *Gata-4* and *cTnI*, in rat bone marrow mesenchymal stem cells through a positive loop with the canonical Wnt signaling. This study relied on lentiviral-mediated *miR-499* overexpression at ~16.5 fold levels vs control, and target gene levels were quantified at 3 days post-transduction [75]. However, these results were obtained in vitro and further proofs are needed to establish their relevance in vivo.

Genetically clustering with *miR-499*, *miR-208a* and *miR-208b* have gained much attention as regulators of hypertrophic remodeling and therefore as potential therapeutic targets. Remarkable for such perspective is that systemic delivery of LNA-enhanced *anti-miR-208a* counteracted cardiac dysfunction in response to hypertension-induced hypertrophy in rats. Administration of 25 mg/kg *anti-miR-208a* appeared sufficient to reduce *miR-208a* levels in the cardiac tissue by ~70% at 14 days post-injection. Intriguingly, analogous effects were obtained through either intravenous, or intraperitoneal, or subcutaneous delivery [76]. *miR-208a* is embedded in one intron of *Myh6*, encoding for α -Myosin heavy chain (α -MyHC), whereas *miR-208b* and *miR-499* are embedded in introns of *Myh7* and *Myh7b*, both encoding for β -MyHC. β -MyHC, characterized by a slower ATPase activity, is mainly expressed in the fetal heart and upon hypertrophic adverse remodeling. Conversely, α -MyHC is upregulated early after birth and accounts for >90% of cardiac MyHC content in the adult heart. T3 signaling promotes the expression of *Myh6* and *miR-208a* through a positive response element, while inhibiting the expression of *Myh7/7b* and *miR-208b/-499* through a negative element [77]. Upon cardiac stress, *miR-208a* binds and represses T3 co-regulator *Thrap-1*, removing the transcriptional block from *Myh7/7b* loci, thereby promoting the switch to β -MyHC. Hypertrophic remodeling is reinforced by *miR-208a*-mediated repression of *Myostatin* [78]. Furthermore, once expressed together with *Myh7/7b*

in the damaged myocardium, *miR-208b* and *miR-499* target *Sox-6*, *Pur- β* and *Sp-3*, known repressors of *Myh7*, thus reinforcing the pathological switch to the slow MyHC isoform [79]. Notable for translational approaches relying on these miRs is that *miR-208a-null* mice did not upregulate β -MyHC under stress, thus suggesting that *miR-208a* is hierarchically upstream of *miR-208b* and *miR-499* [78]. Therefore, the molecular switch between *miR-208a* and *miR-208b/miR-499* appears a therapeutic target for the treatment of cardiac muscle hypertrophy. Sustained inhibition of this switch is indeed a novel way to counteract the adverse hypertrophic remodeling, which is a prominent complication in many chronic conditions of the heart.

3.2. MiRroring cardiac muscle diseases

Besides the *miR-208a/miR-208b/miR-499* circuitry, other miRs have been implicated in the aberrant switch to fetal programs in response to cardiac stress. Transient pulse of 100 nmol *pre-miR-21/-129/-212* in rat neonatal cardiomyocytes caused hypertrophy and re-activation of a fetal cardiac gene program at 48 h post-transfection. Moreover, human fetal cardiac tissues and biopsies from end-stage heart failure patients presented upregulation of these miRs, among others [80]. *MiR-21*, *-129* and *-212* hence appear part of a fetal miR signature that is reactivated in the failing ventricular myocardium. These miRs share many direct and indirect targets among cardiac differentiation or remodeling genes [80]. Several studies have especially focused on *miR-21*, reporting contrasting effects on cardiomyocyte survival and cardiac fibrosis. *MiR-21* expression was found downregulated in the myocardial infarct and upregulated in the border zone. Temporary (10 s) perfusion of infarcted hearts with 200 μ l *miR-21*-bearing adenoviral units resulted in reduction of infarct size by 29% at 24 h post-insult. Moreover, the cardioprotective effect of *miR-21* overexpression has been linked to direct inhibition of one of its targets, *Pdcd-4*, which triggers cardiomyocyte apoptosis [81]. However, a reciprocal loop between *miR-21* and *Tgfb3r-III*, a negative regulator of Tgf β signaling and collagen deposition, has been proposed as possible infarct-triggered mechanism for cardiac fibrosis [82]. Other miRs potentially involved in cardiac fibrosis are *miR-29* and *miR-101* [83]. The *miR-29* family is reduced after acute myocardial infarction (AMI) and targets multiple factors involved in the fibrotic matrix, such as collagens, fibrillins and elastin [84,85]. *MiR-101a/b* are also down-regulated after AMI, and their overexpression inhibited cardiac fibroblast proliferation and collagen deposition, by repressing *cFos* and *Tgfb1* pathways [86]. Manipulation of fibrosis-specific miRs is obviously palatable for post-AMI care. However, a more refined knowledge of the cell types interested by these miR networks will be fundamental to advance translational research on this aspect.

A still puzzling example of fetal cardiac miRs playing a role in adult cardiac stress is *miR-138* [87]. It has been recently demonstrated that *miR-138* stimulates survival of a rat CPC cell line in conditions of hypoxia. The study compared the effects on rat CPCs treated either with 50 nmol *pre-miR-138*, or 100 nmol *anti-miR-138*, at 72 h post-transfection. *MiR-138*-driven amelioration of survival appeared dependent on *Mlk-3* targeting and the consequent repression of its downstream targets *Jnk/cjun* [88]. To date, *miR-138* is the only miR directly linked to cardiac patterning and ventricle chamber formation. The developmental role of *miR-138* resides, at least partially, in the negative regulation of the retinoic acid pathway. This negative loop leads to repression of *Versican*, a cell adhesion molecule usually restricted to the atrioventricular canal [89]. However, this evidence was gathered in zebrafish and the function of *miR-138* during mammalian development remains unknown. Although *miR-138* was also found upregulated in myocardial samples from patients exhibiting congenital heart disease, further molecular links are required in order to properly address the relevance of *miR-138* cardioprotective role in vivo.

A fetal trait potentially useful to counteract post-ischemic dysfunctions is cardiomyocyte proliferation, which is also partly regulated by

miRs. A wide adeno-associated virus-based screen of human miRs identified several miRs, including *miR-199a* and *miR-590*, as robust inducers of cardiomyocyte proliferation. These miRs induced ventricle hypertrophy and long-term resistance to permanent ligation of the coronary artery. Intriguingly, intracardiac delivery of 2.8 µg mimics of human *miR-199a/590* in rat neonatal hearts after birth resulted in enlarged ventricular wall without fibrosis at 3 weeks of age. According experiments were performed in neonatal mice after birth, through intraperitoneal delivery of miR-bearing adeno-associated viruses (10^{11} AAV-9 units). *MiR-590* and *-199a* resulted overexpressed by ~250 fold and ~5 fold, respectively, and significant rates of proliferation of post-natal cardiomyocytes, but not fibroblasts, at 12 days of age were observed [90]. Similarly, *miR-17-92* family members mediate a similar phenotype by targeting *Pten* [91]. These studies provide a promising genetic evidence for putative applications, although a viral-free system of miR delivery with sufficient efficiency in vivo is still missing for human cardiomyocytes.

3.3. MiRs involved in heart failure

Many miRs have been reported altered in conditions of heart failure (Fig. 2). One common cause of heart failure is dilated cardiomyopathy, which is common for the dystrophic myocardium [92]. Comparing patients with dilated and ischemic cardiomyopathies, common trends emerged, such as upregulation of *miR-100* and *miR-195*, and downregulation of *miR-92* and *miR-133b* [93]. *MiR-195* is of particular interest in this context, as *miR-195*-overexpressing mice display adverse hypertrophic remodeling leading to heart failure [77]. *MiR-195* is part of the broadly expressed *miR-15* family, whose members are variably involved in cell proliferation regulation. Recently, LNA-enhanced antagomiRs inhibiting *miR-15* family components have been proven effective in protecting against cardiac ischemic injury. Intravenous delivery of 0.5 mg/kg and 1 mg/kg antagomiRs in mice and pigs appeared sufficient to reduce the cardiac levels of *miR-15* by ~72% and ~90%, respectively, in conditions of *miR-15*-inducing cardiac stress. Interestingly, despite rapid clearance from the blood stream after 12 h, antagomiR levels remained detectable and effective for inhibition till 1 week post-injection. Also, systemic delivery of 0.5 mg/kg *anti-miR-15* oligonucleotides in mice was associated with reduced infarct size and elevated cardioprotection, and alleviated cardiac dysfunction after ischemia–reperfusion injury [94]. Another non-muscle-specific miR involved in cardioprotection against ischemia is *miR-24*, which targets the pro-apoptotic factor *Bcl2l-11*. Immediately after experimental ischemia, *miR-24* was upregulated in injured rat hearts. Also, *miR-24* was interrogated in rat cardiomyocytes cultured in ischemic-mimicking conditions (serum starvation, hypoxia) by means of 100 nmol miR-mimic. Treated cardiomyocytes presented an ~6 fold increase in *miR-24* levels, and reduced rates of in vitro apoptosis and necrosis. These findings and the evidence that hypoxia-triggered *Hif-1* activates *miR-24* suggest that

miR-24 is part of a defective endogenous response enabled by hypoxic cardiomyocytes, and that it is potentially targetable to improve survival [95]. In addition, *miR-24*, *miR-21* and *miR-221* constitute a minimal, defined miR cocktail, amenable to improve survival in murine CPCs both in vitro and in vivo. Combined transduction with single miR-bearing lentiviruses, in fact, resulted in sustained CPC survival after transplantation in both striated muscle compartments, according to bioluminescence-based, non-invasive imaging. Consequently to the longer survival in vivo, transduced CPCs showed also enhanced effects on the functional outcome of injured hearts [96]. Furthermore, an intriguing miR-regulated pathway in different heart failure etiologies is the calcium flux regulation. An example of such context is *miR-214*, which was found upregulated in several conditions of heart failure and hypertrophy. *MiR-214* protects against excessive calcium uptake by repressing a $\text{Na}^{2+}/\text{Ca}^{2+}$ exchanger (*Ncx-1*), a calmodulin-dependent kinase (*Camk-II γ*), a mitochondrial permeability modulator (*Cypd*), and, once again, the pro-apoptotic *Bcl2l-11* [97]. In the same context, *miR-133a* has been recently linked to the calcium channel *Ip3r-II* in a mutual repressive loop, which regulates calcium signaling and pathological cardiac remodeling [98].

MiRs can also target the myogenic remodeling by affecting key epigenetic regulators [99]. An example consists of *miR-22*, which promotes hypertrophic remodeling in cardiomyocytes [100]. Transfection of rat neonatal cardiomyocytes with 50 nmol *miR-22-mimic* resulted in upregulated hypertrophic markers in both presence and absence of phenylephrine, a hypertrophic agonist. Accordingly, genetic ablation of *miR-22* decreased cardiac hypertrophic remodeling in vivo. Targets of *miR-22* include the deacetylases *Sirt-1* and *Hdac-4*, both involved in the myogenic progression [101]. *Sirt-1* is also targeted by another miR involved in cardiac senescence and failure, *miR-34a*. Pre-treatment of bone marrow mononuclear cells with 500 nmol LNA-enhanced *anti-miR-34a* improved cell survival and engrafting capacity in vivo, in experimental conditions of AMI [102]. Besides its effects on epigenetic regulators, *miR-34a* targets anti-apoptotic *Bcl-2* and cell cycle promoters *Cyclin-D2* and related kinases, thus promoting apoptosis and senescence [103]. Considering the theoretical concerted repression of *Cyclin-D2* exerted by *miR-133a* and *miR-34a*, it would be interesting to know whether this holds true in cardiac regeneration and remodeling.

3.4. Skeletal myogenesis and miRs

A wide range of miRs tightly control skeletal muscle formation and regeneration (Table 2). Similarly to the cardiac muscle, myomiRs play a pivotal role in regulating myoblast commitment and skeletal muscle formation [104]. *MiR-1* promotes differentiation of cultured myoblasts through translational repression of *Hdac-4*, which represses *Mef-2*-dependent expression of myogenic factors [105,106]. Conversely, *miR-133* stimulates myoblast proliferation mostly through negative regulation of *Srf* [107], thus creating a similar negative feedback loop as

Table 2

MiR manipulation strategies relevant for normal or aberrant skeletal myogenesis.

miR	Target	Means of manipulation	Effects	Ref
<i>miR-1/-206</i>	Murine satellite cells	Adenoviral transduction	skeletal myogenic differentiation	[110]
<i>miR-1/-206</i>	Murine neonatal skeletal muscles	AntagomiR delivery (systemic/intramuscular)	proliferation of myogenic cells	[110]
<i>miR-1/-206</i>	Murine pre-segmented embryos	AntagomiR delivery	skeletal myogenic differentiation	[111]
<i>miR-27b</i>	Murine adult muscle (acute injury)	AntagomiR delivery (intramuscular)	proliferation of myogenic cells	[115]
<i>miR-181</i>	Murine myoblasts	AntagomiR transfection	skeletal myogenic differentiation	[116]
<i>miR-214</i>	Murine satellite cells	Lentiviral transduction	skeletal myogenic differentiation	[120]
<i>miR-29</i>	Murine myoblasts/rhabdomyosarcoma cell line	miR-mimic transfection	skeletal myogenic differentiation	[122]
<i>miR-23a</i>	Murine adult muscle (experimental atrophy)	Plasmid transfection	skeletal muscle atrophy	[136]
<i>miR-669a</i>	Murine neonatal cardiac/skeletal muscles	AAV2/9 delivery (intracardiac/intramuscular)	skeletal myogenic aberrant conversion/differentiation	[139,140]

The table presents several cases and effects of miR manipulation in myogenic cells or skeletal muscle, with potential relevance to applications involving myogenic regeneration in normal, aberrant or chronic disease conditions.

described for CPCs. During skeletal myogenesis, together with *Srf* and *Mef-2*, *MyoD* and *Myogenin* co-regulate *miR-1* and *miR-133* transcription (Fig. 3). Importantly, in combination with *Srf*, *MyoD* activates *miR-486*, which in turn represses *Pten* and *FoxO-1a*, reinforcing the Akt signaling and enhancing muscle growth. Transgenic fate tracking showed that *miR-486* is expressed throughout somite-to-muscle formation stages [108]. Hence, *miR-486* appears an important link between *MyoD* and the Akt signaling during skeletal muscle formation. This notion has been recently explored through a *miR-486*-based transgenic system to counteract muscle wastage in a murine model of Duchenne MD [109].

A specific myomiR for the skeletal muscle is *miR-206*. Overexpression of *miR-206* in combination with *miR-1*, by means of adenoviral transduction, induced premature differentiation of primary murine satellite cells, by targeting *Pax7* 3'-UTR. Conversely, administration of 80 mg/kg *anti-miR-1/-206* in neonatal mice induced a significant increase of *Pax7*⁺/*Brdu*⁺ proliferating cells in the skeletal muscle at 24 h post-injection. Noteworthy, this effect was obtained at comparable levels through both intramuscular and intraperitoneal delivery [110]. Furthermore, injection of antagonomiRs targeting *miR-1/-206* in pre-segmented murine embryos resulted in dramatically decreased *Myogenin* expression and perturbed myogenic development. This effect was traced to the ability of *miR-1* and *miR-206* to bind two conserved regions on the 3'-UTR of *Pax3*, a myogenic factor sustaining the myoblasts in an immature state [111]. *MyoD* and *Myogenin* recognize *miR-206* upstream enhancer and activate its expression. *miR-206* promotes myoblast differentiation by repressing many targets, including *Pola-1*, the largest DNA polymerase subunit, thereby halting the proliferation machinery in favor of differentiation [112]. In addition, *miR-206* targets gap-junction

Cx43 [113], hence putatively promoting the terminal maturation of skeletal fibers. Also, *miR-206* has been implicated as regulator of a spontaneously mutated *Myostatin* 3'-UTR, likely causing muscle mass overgrowth in the Belgian Texel sheep [114].

Analogously to the cardiac muscle, myomiRs *miR-208b* and *miR-499* are upregulated also in slow skeletal muscle fibers following *Myh7/7b* expression, and reinforce the switch to β -MyHC in the presence of calcium-related fiber stress [79].

Subsequently to the exit from the proliferative state, *miR-27b* and *miR-181* contribute to prime the differentiating cells along later stages of skeletal myogenesis. *miR-27b* further promotes progression of the differentiation by translationally repressing *Pax-3*. Lentiviral-mediated *miR-27* overexpression in somite explant cultures drastically reduced *Pax3*⁺ and increased *Myogenin*⁺, committed progenitors. Accordingly, intramuscular injection of 10 μ mol *anti-miR-27b* upon acute muscle injury resulted in increased number of *Pax3*⁺ satellite cells. As a consequence, the muscle regeneration appeared delayed, although the effects were quantified at a rather early stage (6 days) post-injury [115]. Similarly, *miR-181* indirectly activates *MyoD* by targeting one of its negative regulators, *HoxA-11*. Transfection of murine myoblasts with *miR-181*-targeting antagonomiR, in fact, affected in vitro myotube formation. However, it is intriguing to note that, in the same experimental model, *miR-181*-mimic was not altering myoblast differentiation. This suggests that the endogenous levels of *miR-181* are normally sufficient to reach effect-exerting plateau [116]. Other regulators of the balance between proliferation and differentiation in myogenic cells are *miR-322* and *miR-503*, which target cell cycle promoter *Cdc-25a*, although the evidence is at present limited to one myoblast cell line in vitro [117,118].




Fig. 3. Complexity of miR-based regulations in skeletal myogenesis. This diagram depicts several pathways presented in this review, in order to synthesize the information gathered from differentiating muscle progenitors and diseased skeletal fibers. Genes are pseudocolored according to their function (legend), whereas miRNAs are pseudocolored according to the cognate process (arrows and squares). The same miRNAs can have different colors in accordance with the different contexts in which they are depicted. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

As in cardiac myogenesis, epigenetic and post-transcriptional controls are complexly entwined with miRs in skeletal muscle formation [119]. An example of miRs driving indirect epigenetic regulation is *miR-214*. Lentiviral-mediated overexpression of *miR-214* up to ~5 fold endogenous levels increments the number of Myogenin⁺ differentiating cells in primary cultures of myofiber-derived satellite cells. *MiR-214* positively regulates *Myogenin*, *Ckm* (creatine kinase, CK) and *Myh* (myosin heavy chain) by targeting their negative epigenetic regulator *Ezh-2*, member of the Polycomb repressive complex [120]. This regulation seems important for normal skeletal muscle development, as transgenic ablation of *miR-214* results in embryonic lethality and severe skeletal muscle defects [121]. Yet an example of miR-epigenetics feedback loop is highlighted by the case of the pro-myogenic *miR-29*. Transfection of 50 μ mol *pre-miR-29* oligonucleotides, but not the mutated control, increased expression up to ~3000 fold basal levels and associated with higher expression of terminal markers of skeletal myogenesis in murine myoblasts. Intriguingly, the same treatment appeared effective also on rhabdomyosarcoma cell lines, which consequently displayed slower rates of growth. Downstream of NF- κ B circuitry, *miR-29* is repressed by, and in turn represses, chromatin remodelers *Rybp* and *Yy-1* [122,123]. Conversely, alternative polyadenylation and long-noncoding RNAs constitute two possibilities of refined post-transcriptional control on myogenic miR activity. In the first case, a reported example is the alternative polyadenylation of *Pax-3*, which presents *miR-206* target site at its 3'-UTR only after the onset of differentiation [124]. In the second case, *linc-MD1* serves as competing sponge to titrate *miR-133* and *miR-135* away from their targets, *Maml-1* and *Mef-2C*, further allowing myoblast differentiation [125]. Intriguingly, *Maml-1* and *Mef-2C* have been reported as important fate regulators also in human mesoangioblasts [126]. This notion opens the enticing question whether *linc-MD1* might represent a novel target to enhance the potential of myogenic cells amenable for systemic delivery. However, to address this translational perspective, molecular tools to modulate long-noncoding RNAs must first be refined and upscaled.

3.5. MiRroring skeletal muscle diseases and fate switch

Chronic muscle disorders disrupt miR circuitries, raising the intriguing possibility of disease-specific miR signatures traceable in muscle biopsies [127]. This point would be particularly useful to help physicians and biologists in discriminating between the diverse forms of chronic myopathies and dystrophies, often mistaken without the support of a complete genetic screen. In this regard, *miR-299-5p*, *-487b*, *-362* have been reported as specifically upregulated in Duchenne MD, whereas inflammatory *miR-155*, *-146b* would characterize inclusion body- or dermato-myositis. Moreover, *miR-381*, *-382* would mark the facioscapulohumeral MD, and *miR-100*, *-103*, *-107* would hallmark limb-girdle MDs when compared to Duchenne MD [128,129]. Analogously, miR signatures potentially characterizing sarcopenia are intensively investigated, for instance during aging [130, 131]. In mice, it has been reported that *miR-7/-206/-468/-542/-698* are upregulated in aged muscles, whereas *miR-124a/-181a/-221/-382/-434/-455* are upregulated in adult control muscles [132]. When comparing muscle miR signatures between old and young individuals in primates, it has been reported that aged muscles presented downregulation of *miR-181a* and upregulation of *miR-15a/-18a/-144/-451* [133]. Despite the quantitative differences, further experiments are required to pinpoint the downstream targets and the biological role of such signatures. Interestingly, in human muscles, not only did mature miRs exhibit differential expression upon aging, but also pri-myomiRs, e.g. *pri-miR-1* and *pri-miR-133a*, presented higher levels [134,135]. This evidence opens the question whether the pri-miR accumulation in elderly muscles is due to deficiencies in the maturing machinery or to aging-specific cues.

In addition to aging, muscle atrophy also causes muscle mass loss, often as a consequence of chronic diseases. In this context, *miR-23a*

plays an important role, as dexamethasone-induced atrophy of murine adult skeletal fibers is attenuated after transient pulse of a *miR-23a*-expressing plasmid. Consistently, *miR-23a*-overexpressing mice displayed resistance to dexamethasone-induced atrophy. It has been shown that *miR-23a* targets the 3'-UTR of both *Atrogin-1* and *Murf-1*, which mediate atrophy-associated protein degradation [136].

A fascinating perspective for miRs in striated muscle control resides in their role in myogenic fate switches. Murine dystrophic cardiac mesoangioblasts presented the aberrant propensity to differentiate into skeletal muscle fibers, which were functionally uncoupled from the surrounding myocardium and contributed to progressive exacerbation of the dilated cardiomyopathy [137,138]. The pathological myogenic switch has been imputed to *miR-669a/q*. Indeed, transduction of the neonatal murine myocardium with *miR-699a*-expressing AAV2/9, but not with scramble-bearing AAV, resulted in traceable, life-long miR overexpression (~6 fold endogenous levels at 18 months of age) and partially alleviated end-stage dystrophic cardiomyopathy [139]. *MiR-669a/q* are negative regulators of *MyoD* and are repressed in *Sgcb-null* murine cardiac mesoangioblasts, owing to two concerted mechanisms. *MiR-669a* lies within the intron 10 of *Sfmbt* gene, whereas intron 1 of *Sgcb* harbors *miR-669q*. Transgenic deletion of *Sgcb* expression confers the dystrophic phenotype and ablates expression of *miR-669q*. In addition, intracellular calcium leakage, typical for dystrophic myocytes, causes degradation of *Yy1*, activator of *Sfmbt*, and downregulation of *miR-669a* [140]. Albeit a direct human ortholog of *miR-669a/q* is still unidentified, *MYOD* re-expression in cardiac cells was reported for two subjects with oncocytic cardiomyopathy [141], thus opening the question of which miRs can be targeted to counteract pathological myogenic switches in patients.

3.6. MiRs, not miRacles: hints from and for regenerative medicine

In order to translate the findings about miRs and related targets (Table 3) into clinical-grade solutions for striated muscles, it will be

Table 3
Relevant miRs and targets in cardiac and skeletal myogenesis.

miR	Reported target genes in cardiac myogenesis	Reported target genes in skeletal myogenesis	Ref.
<i>miR-1</i>	<i>Calmodulin; Dll-1; Hand-2; Mef-2a</i>	<i>Hdac-4; Pax-3;</i>	[63,66,67, 105,111]
<i>miR-17-92</i>	<i>Pten</i>		[91]
<i>miR-21</i>	<i>Pdcd-4; Tgfb3r-III</i>		[81,82]
<i>miR-22</i>	<i>Hdac-4; Sirt-1</i>		[101]
<i>miR-23a</i>		<i>Atrogin-1; Murf-1</i>	[136]
<i>miR-24</i>	<i>Bcl2l-11</i>		[95]
<i>miR-27</i>		<i>Pax-3</i>	[115]
<i>miR-29</i>	<i>Col1-a1; Col1-a2; Col3-a1; Eln-1; Fbn-1;</i>	<i>Rybp</i>	[84,122, 123]
<i>miR-34a</i>	<i>Bcl-2; Cyclin-D2; Sirt-1</i>	<i>Yy-1</i>	[102,103]
<i>miR-101</i>	<i>cFos; Tgfb31</i>		[86]
<i>miR-133</i>	<i>Cyclin-D2; Ip3r-II; Srf</i>	<i>Maml-1; Mef-2c; Srf</i>	[64,65,98, 107,125]
<i>miR-135</i>		<i>Maml-1; Mef-2c</i>	[125]
<i>miR-138</i>	<i>Aldh1-a2; Cspg-2; Mlk-3</i>		[88,89]
<i>miR-181</i>		<i>HoxA-11</i>	[116]
<i>miR-199a</i>	<i>Clic-5; Homer-1; Hopx</i>		[90]
<i>miR-206</i>		<i>Cx43; Myostatin (mutated); Pax-3; Pax-7; Pola-1</i>	[110–114, 124]
<i>miR-208a</i>	<i>Myostatin; Thrap-1</i>		[77,78]
<i>miR-208b</i>	<i>Pur-β; Sox-6; Sp-3</i>	<i>Pur-β; Sox-6; Sp-3</i>	[79]
<i>miR-214</i>	<i>Bcl2l-11; Camk-IIy; Cypd; Ncx-1</i>	<i>Ezh-2</i>	[97,120]
<i>miR-486</i>		<i>FoxO-1a; Pten</i>	[108]
<i>miR-499</i>	<i>Pur-β; Rod1; Sox6; Sp-3</i>	<i>Pur-β; Sox-6; Sp-3</i>	[70,79]
<i>miR-590</i>	<i>Clic-5; Homer-1; Hopx</i>		[90]
<i>miR-669a/q</i>	<i>MyoD (aberrant switch)</i>	<i>MyoD</i>	[139,140]

The table summarizes several miRs and related target genes as reported throughout the review.

fundamental to address the issues of specific tissue targeting and timely *in vivo* effects of miR-based strategies.

The aforementioned systemic delivery of *anti-miR-208a* is a brilliant example of a therapeutic approach with beneficial effects restricted to the heart, without reported side effects in the skeletal muscle or in other districts [76]. Although it remains unknown whether such approach is upscalable to humans, its successful outcome is likely due to the natural properties of *miR-208a* and to the intrinsic characteristics of the disease model. *MiR-208a* is cardiac-specific and prominently down-regulated after birth, and it is generally re-activated only under pathological remodeling [77]. Moreover, hypertension-prone Dahl rats do not present evident damage in the skeletal muscles [142]. Conversely, when miRs can act in both striated muscle types, their modulation must be confined to the desired district. An example is *miR-669a* manipulation, which induced beneficial effects in the degenerating heart, but also a potentially negative response in regenerating skeletal fibers [140]. In that respect, *miR-206* could be a candidate miRNA for a therapeutic approach focused on the skeletal muscle compartment, owing to its rather specific targets. However, before approaching strategies of *miR-206* modulation by means of systemic delivery, it will be primarily important to exclude that *miR-206* can induce any aberrant fate switches in resident cardiomyogenic cells.

Other approaches that should be considered for therapeutic advances, possibly in combination, are the multimodal miR modulation and the timely delivery. Multimodal miR modulation consists of combining up- and downregulation of different miRs in the same regenerative strategy. Although obviously more difficult to optimize, owing to often divergent miR-specific requirements, such approach would theoretically increase specificity and efficacy of systemic deliveries. In that respect, it might be interesting to combine the modulation of myomiRs with survival-enhancing miRs in cardiac-oriented strategies, and with epigenetics-regulating miRs in skeletal-oriented strategies. Particularly with regard to myomiR modulation, time-specific dosages will probably increase the applicative potential of translational strategies. Consistently with this notion, it will be useful to determine relative time sequences for the modulation of *miR-1/-133/-499*, in combination with either *miR-208a*, as cardiac-specific, or *miR-206*, as skeletal muscle-specific. Moreover, timely modulation of different myomiRs might be applied to systemic approaches *in vivo*, considering the transient effects and the rapid clearance of miR-mimics or antagomiRs. Such *in vivo* strategies will be particularly relevant when addressed in appropriate animal models of acute or chronic muscle damage. Refinement of these studies will likely enable us to better articulate the myomiR-driven regenerative response in the two striated muscle types.

A critical point for progressing miRs as pharmaceutical tools in the regenerative medicine for striated muscle is the means of miR modulation. Notwithstanding recent advances in conjugation and chemistries, oligonucleotides still appear mainly ideal for applications limited in time, owing to short half-life after systemic delivery and often problematic upscaling. AAVs, especially considering the tropism of serotypes 2 and 9 for striated muscles, are experimentally rather potent and ensure miR-modulation on the long term. However, their clinical application appears presently blunted, due to the risks posed by random genomic insertions [143]. In this regard, a putative alternative could be the combination of tissue engineering and miR modulation technologies. Appropriate stem cell pools, possibly with scaffolds enhancing their survival and commitment, might be engineered as *in vivo* paracrine hubs of miR modulation. The cell implant would then provide the host tissue with specific beneficial miRs or anti-miRs. Importantly, the choice of the stem cell pool will potentially influence specificity and directionality of miR modulation in host cell types. This has indeed been reported in the opposite direction for the miRcrine cross-talk between cardiomyocytes and cardiac stem cells [73].

Lastly, translational research on miRs governing striated muscle regeneration will definitely take advantage of a deeper understanding of the cell-to-cell patterns and the causal relationships between miRs

and downstream biological effects. In this perspective, a necessary path will consist of interrogating the complex regulation/effects of circulating miRs in experimental models and clinical cases of striated muscle regeneration. Therefore, the last part of this review will focus on the rapidly expanding field of exosome-borne and circulating miRs (circ-miRs).

4. Exosomal and circulating miRs in striated muscle regulation

4.1. Exosomes: a novel route of miR-based signals for cardiac muscle regulation

The role of exosomes as signaling shuttles for short- and long-range communication between cells and striated muscle tissues has recently emerged (Figs. 2–3). In the plasma of healthy individuals, exosomes are present in a surprisingly high concentration ($\sim 10^{10}$ /ml) [144], suggesting a physiological signaling role beyond the pathological shedding of cell debris. Exosomal cargo may contain proteins, mRNAs and miRs, and accumulating evidence is implicating exosomal miRs in a variety of cardiac and skeletal muscle conditions.

Since the first ultrastructural evidence of exosome secretion by CPCs and cardiosphere-derived cells (CDCs) [145], several other studies have reported on exosomal miRs influencing cardiomyogenic cell behavior. *In vitro*, rat CPCs have been shown to secrete exosomes enriched in *miR-133a* after cell death induced by calcium ionophore treatment. Exosomal *miR-133a* resulted functionally transferred to non-cardiac cells [146]. *In vivo*, CPC-derived exosomes, enriched in *miR-451*, significantly decreased cardiomyocyte apoptosis in AMI, likely through repression of *Caspase3/7* [147]. In addition, exosomes have been shown to mediate CDC-driven regenerative effects in the heart, partly by shuttling *miR-146a* [148]. Furthermore, exosomes have been implicated in an experimental model of cardioprotective ischemic preconditioning. This model consists of brief insults in remote myocardial areas to ameliorate the outcome of subsequent sustained ischemia [149]. Moreover, exosome-borne *miR-22* has been demonstrated to partly mediate the cardioprotective effect of ischemic preconditioning by targeting the epigenetic regulator *Mecp-2* [150]. *Mecp-2* exerts pleiotropic effects on several factors regulating survival or apoptosis, although this has currently been demonstrated only in non-muscle contexts [151–153]. These observations partially match previous findings showing the exosome-mediated beneficial effects of human mesenchymal cells on ischemia/reperfusion injured myocardium [154]. Conversely, resident miRs can also be regulated by exosomal proteins/transcripts, as it has been reported for *Sca-1⁺* CPCs shuttling *Hsf-1* into ischemic cardiomyocytes, leading to epigenetic repression of *miR-34a* and improved survival [155].

Exosomes are probably involved in shuttling circ-miRs between different tissues in pathological conditions. Increased levels of *circ-miR-1* and *-miR-208* were found in the urine of AMI-affected rats. These circ-miRs have been linked to exosome shuttling from the injured heart through the kidney [156], although the observation was gathered from re-injection of exosomes in the animals. Recently, fibroblast-derived exosomal *miR-21** has been identified as a pro-hypertrophic factor in cardiomyocytes, where it represses *Sorbs-2* and *Pdlim-5* [157]. Furthermore, *circ-miR-214* was found altered in CAD patients [158]. It has also recently been shown that *miR-214* constitutes a fundamental part of the cargo of pro-angiogenic exosomes secreted from endothelial cells [159]. However, a direct proof of functional uptake of endothelial-borne exosomal miRs by injured myocardial cells *in vivo* is still missing.

4.2. Exosome-borne miRs for skeletal myogenesis regulation

Exosomal miRs are attracting increasing levels of attention within the context of skeletal myogenesis. In fact, engineering pharmacological or stem cell-mediated formulations of targeted exosome-borne miRs constitutes an enticing translational perspective for enhancing myogenic regeneration [160]. In support of this speculation, CD34⁺ stem cells

were engineered to release exosomes enriched in the Hedgehog signaling agonist Shh, which has pro-angiogenic effects. Functional transfer of Shh was evident *in vitro*. Moreover, after injection of the engineered CD34⁺ cells in the border zone, the myocardial infarct size was reduced, the capillary density was increased, and the functionality resulted improved on the long term [161]. Furthermore, artificial formulations of exosomes carrying specific miRs have already been successfully tested to target the murine brain after systemic delivery [162]. A fascinating putative path will consist of combining specific exosomal-miR formulations with transmembrane signaling proteins able to interact with the endogenous myogenic stem cells, such as Notch ligands [126, 163]. In line with this idea, a feedback circuitry involving *miR-126* and *Dll-4* in mesenchymal stem cells has already been linked to pro-angiogenic remodeling in the ischemic myocardium [164].

Of potential significance for the translational concept of stimulating resident progenitors is the notion that myoblasts secrete exosomes [165], although with different content types and effects during the proliferation and the differentiation stages *in vitro* [166]. Myotube-derived exosomes, in fact, promoted differentiation of target myoblasts by down-regulating *Cyclin-D1* and *Myogenin* [167]. Yet the question remains of whether *miR-186*, *-329* and *-362* are involved, as these are predicted binders of the 3'-UTRs of both genes. Intriguingly, using the same myoblast model, atrophic myotubes presented decreased intracellular levels, but increased exosomal fractions of *miR-23a* [168] and *miR-182* [169]. This observation suggests a selective exosome-loading of miRs under stress conditions. Despite being promising, the field of exosomal miRs in skeletal myogenesis will definitely need more exhaustive investigation in a wider range of muscular disorders and regenerative strategies *in vivo*.

4.3. *Circ-miRs: biomarkers and/or effectors in the context of cardiac damage?*

During the last decade, evidence has accumulated from animal models and clinical studies, pointing at circ-miRs as novel biomarkers of the striated muscle condition. Circ-miR levels in serum and plasma are indeed readily detectable and appear altered in a variety of conditions. Although many issues must still be overcome, particularly in terms of sensitivity and feasibility [170,171], circ-miR analysis could in principle improve the presently used diagnostic or prognostic tools. Indeed, circ-miRs, especially as signatures, might help in focusing the current diagnostic tools, such as circulating CK, myoglobin or troponins, often altered by issues unrelated to the striated muscle pathology [172,173]. When approaching this exciting body of literature, however, an important caveat to consider is the still substantial lack of experimental evidence discriminating between the circ-miRs effecting a signal and the circ-miRs derived from an affected muscle.

Several studies have linked the circulating levels of *miR-1*, the most abundant miR in striated muscle, with acute or chronic conditions of muscle damage [174]. Indeed, the first evidence of increased plasma levels of *circ-miR-1* in AMI patients [175] was consolidated by pre-clinical studies, documenting *circ-miR-1* time peaks in AMI animal models. Serum levels of *circ-miR-1* correlated with release of the cardiac-specific CK isoform and with infarct size [176].

Circulating levels of myomiRs were found significantly increased in the aortic flow and correlated with serum levels of troponin-T (current standard of indirect measurement of myocardial damage) in acute coronary syndrome (ACS) patients, when compared to troponin-negative patients with coronary artery disease (CAD). Intriguingly, this study also reported that endothelium-enriched *miR-126* inversely correlated with the extent of myocardial injury, suggesting that *miR-126* is consumed during the trans-coronary passage through either uptake or turnover [177].

Further possible implications of these findings relate to the role of *miR-499* in hypertrophic cardiac remodeling [178] and on the complex vascular regulations exerted by *miR-126*. Indeed, *miR-126* stimulates

angiogenesis by repressing *Spred-1* and *R2-p58β*, negative regulators of the *Vegf* signaling [179]. *MiR-126* also decreases inflammatory cell recruitment and extravasation by repressing *Vcam-1* [180]. Accordingly, plasma levels of *circ-miR-1* and *-miR-126* have been reported as increased and decreased, respectively, at 4 h after the onset of symptoms, when comparing AMI patients to healthy control subjects [181]. The paracrine effects of *miR-126* have also been documented in CD34⁺ cell-derived exosomes, which improved post-ischemic conditions by stimulating angiogenesis [182,183]. In this regard, it is intriguing to note that diabetes mellitus patients displayed CD34⁺ cells with impaired paracrine functions and that *miR-126* overexpression was able to revert their dysfunctionality [184]. Thus, this evidence links the known neovascularization defects of diabetes mellitus to cardiac cells by means of miR-bearing exosomes. Another recent study of miR-based trans-coronary biomarkers identified *miR-423-5p* as a cardiac-specific heart failure plasma marker, positively correlating with the b-type natriuretic peptide [185]. Interestingly, *miR-423-5p* has also been reported, in combination with *miR-499*, as a putative biomarker discriminating congestive heart failure from AMI [186].

Members of the *miR-133* and *miR-208* families have also been investigated as circulating biomarkers with potential diagnostic and prognostic value. *Circ-miR-133a/b* and *-miR-208a/b* were increased in the plasma of a large cohort of ACS patients. Intriguingly, higher levels of *miR-133b* and *miR-208b* apparently correlated with adverse prognosis [187]. In another study conducted on myocardial infarct patients undergoing primary angioplasty, *circ-miR-133a* levels associated with larger infarcts, higher reperfusion injury and decreased myocardial recovery [188]. Plasma concentration of *circ-miR-208a* resulted augmented in rats after isoproterenol-induced myocardial injury, but not in rats with cardiac hypertensive hypertrophy. This suggests that *circ-miR-208a* is probably linked directly to the cardiomyocyte wastage and that hypertrophy is not per se sufficient to promote *circ-miR-208a* leakage [189]. In addition, *circ-miR-208a* appears to be a more sensitive biomarker of the early phase of AMI, particularly within the first 4 h after onset [190].

4.4. *Circ-miRs in the context of skeletal muscle damage and physical exercise*

Circ-miRs are currently also being scrutinized in relation to skeletal muscle disorders [191]. Serum levels of circ-myomiRs (*miR-1*, *-133a*, *-206*) were found to be increased in both murine and canine models of Duchenne MD [192]. Interestingly, circ-myomiR levels appeared to correlate with disease progression and were poorly influenced by physical or muscle-unrelated stress [193]. Upregulation of these circ-miRs has also been documented in Duchenne MD patients, when compared to age-matched subjects [194,195]. *Circ-miR-206* has been proposed as a biomarker for amyotrophic lateral sclerosis following plasma measurements in a murine model of the disease [196]. Furthermore, circ-myomiR perturbations have been reported for patients with chronic obstructive pulmonary disease [197], which often display muscle atrophy, and in patients bearing rhabdomyosarcoma tumors [198]. In addition, increased *circ-miR-144* has been associated with insulin-resistance in skeletal muscles of diabetic animals and patients [199].

Muscle-related circ-miRs seem appear to be affected not only by the pathological state, but also by physiological activities such as physical exercise. Time-dependent changes in several circ-myomiRs have been observed during recovery from exercise [200]. The type of exercise influences the entity of fiber damage and muscle response, and circ-miR levels might reflect these changes. Plasma myomiR levels indeed increased after muscle-damaging eccentric exercise, i.e. marathon running, but not after concentric exercise, i.e. prolonged biking [201,202]. In addition, a growing body of literature is dedicated to the differences in circ-miRs with respect to the training status preceding diverse exercise modalities [203]. These studies are apparently pointing at circ-miRs as fine diagnostic biomarkers of pathological remodeling

and disease/exercise-induced fiber wastage. However, one cannot exclude the possibility of a defective circ-miR-based signaling, aimed at eliciting survival and adaptation in non-degenerating fibers. Importantly, both contribution and response are still rather poorly distinguishable between cardiac and skeletal muscles in these studies. Thus, further steps towards a systematic evaluation of causality relations are required to disentangle the complex web of circ-miRs.

5. Future perspectives and conclusions

In conclusion, investigation into miR-based feedback circuitries has clearly enriched our current understanding on the myogenic processes during striated muscle specification. Both for cardiac and skeletal myogenic routes, miRs have emerged as refined and potent tools to direct many gene pathways towards a detrimental or beneficial outcome [204]. Still, more work is required to determine how the miRNA interplay critically affects different facets of the myogenic lineage commitment and the adult muscle remodeling. Studying miRNA fluctuations in biomaterial-embedded stem cells would certainly be useful in refining our tools for ex-vivo myogenesis, and in boosting clinical applications. Indeed, the combination of cell-based tissue engineering with dedicated miRNA modulation could be an avenue with potential therapeutic value for striated muscle repair.

Furthermore, through either exosomes or protein carriers, circ-miRs are emerging as possible mediators of long-range biological effects, and as putative biomarkers for more comprehensive diagnoses and prognoses. However, more efforts are needed to shed light on the still numerous open questions. In particular, it will be mandatory to address the directionalities and the causal relationships of miR-based circuitries on a cellular level. Following this perspective, it will be intriguing to decipher how miRs affect the interplay between different cell and stem cell types involved in striated muscle (re)generation. In this context, the combination of induced pluripotent stem cells and next-generation sequencing will be of great benefit in modeling the diverse myogenic cell players, and in unraveling the cross-signaling miR cascades.

Acknowledgments

We would like to apologize to all authors whose work has not been reported here because of space limitations. We would like to thank Dr Andrew J Smith (Centre of Human & Aerospace Physiological Sciences, School of Biomedical Sciences, King's College London, London, UK) for helping us in revising the text and improving readability. This work has been supported by the contributions of "Opening The Future" Campaign (EJJ-OPTFUT-02010), CARE-MI FP7 (#QPG-394601), AFM Telethon (#18073), Programmafinanciering KUL PF/10/00300, CARIPOLO (2007.5639; 2008.2005), FWO (#G060612N, #G0A8813N, #G088715N), GOA (EJJ-C2161-GOA/11/012), IUAP-VII/07 (EJJ-C4851-17/07-P) and OT#09-053 (EJJ-C0420-OT/09/053) grants. MQ is supported by FWO (postdoctoral fellowship) and AFM (trampoline grant #18373). We thank Christina Vochten and Vicky Raets for professional administrative assistance. We would also like to thank Paolo Luban and Rondoufonds voor Duchenne Onderzoek for their kind donations.

References

- A.E.H. Emery, The muscular dystrophies, *Lancet* 359 (2002) 687–695, [http://dx.doi.org/10.1016/S0140-6736\(02\)07815-7](http://dx.doi.org/10.1016/S0140-6736(02)07815-7).
- T. Zaglia, G. Milan, A. Ruhs, M. Franzoso, E. Bertaggia, N. Pianca, et al., Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy, *J. Clin. Invest.* 124 (2014) 2410–2424, <http://dx.doi.org/10.1172/JCI66339>.
- D. Sala, S. Ivanova, N. Plana, V. Ribas, J. Duran, D. Bach, et al., Autophagy-regulating TP53INP2 mediates muscle wasting and is repressed in diabetes, *J. Clin. Invest.* 124 (2014) 1914–1927, <http://dx.doi.org/10.1172/JCI72327>.
- A.E. Moran, M.H. Forouzanfar, G.A. Roth, G.A. Mensah, M. Ezzati, A. Flaxman, et al., The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study, *Circulation* 129 (2014) 1493–1501, <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004046>.
- D. Costamagna, M. Quattrocelli, R. Duellen, V. Sahakyan, I. Perini, G. Palazzolo, et al., Fate choice of post-natal mesoderm progenitors: skeletal versus cardiac muscle plasticity, *Cell. Mol. Life Sci.* (2013) <http://dx.doi.org/10.1007/s00018-013-1445-7>.
- B. Nadal-Ginard, G.M. Ellison, D. Torella, Absence of evidence is not evidence of absence: pitfalls of cre knock-ins in the c-Kit locus, *Circ. Res.* 115 (2014) 415–418, <http://dx.doi.org/10.1161/CIRCRESAHA.114.304676>.
- J.D. Molkenin, Letter by Molkenin regarding article, "The absence of evidence is not evidence of absence: the pitfalls of cre knock-ins in the c-kit locus", *Circ. Res.* 115 (2014) e21–e23, <http://dx.doi.org/10.1161/CIRCRESAHA.114.305011>.
- E.N. Olson, MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease, *Sci. Transl. Med.* 6 (2014) <http://dx.doi.org/10.1126/scitranslmed.3009008> (239 ps3).
- S. Crippa, M. Cassano, M. Sampaolesi, Role of miRNAs in muscle stem cell biology: proliferation, differentiation and death, *Curr. Pharm. Des.* 18 (2012) 1718–1729 <http://www.ncbi.nlm.nih.gov/pubmed/22352753> (accessed October 13, 2014).
- E. Bronze-da-Rocha, MicroRNAs expression profiles in cardiovascular diseases, *Biomed Res. Int.* 2014 (2014) 985408, <http://dx.doi.org/10.1155/2014/985408>.
- A. Shenoy, R.H. Blelloch, Regulation of microRNA function in somatic stem cell proliferation and differentiation, *Nat. Rev. Mol. Cell Biol.* 15 (2014) 565–576, <http://dx.doi.org/10.1038/nrm3854>.
- X. Liu, X. Chen, X. Yu, Y. Tao, A.M. Bode, Z. Dong, et al., Regulation of microRNAs by epigenetics and their interplay involved in cancer, *J. Exp. Clin. Cancer Res.* 32 (2013) 96, <http://dx.doi.org/10.1186/1756-9966-32-96>.
- H.J. Curtis, C.R. Sibley, M.J.A. Wood, Mirtrons, An emerging class of atypical miRNA, *Wiley Interdiscip. Rev. RNA* 3 617–32, <http://dx.doi.org/10.1002/wrna.1122>.
- M. Ha, V.N. Kim, Regulation of microRNA biogenesis, *Nat. Rev. Mol. Cell Biol.* 15 (2014) 509–524, <http://dx.doi.org/10.1038/nrm3838>.
- K.W. Diebel, D.J. Claypool, L.F. van Dyk, A conserved RNA polymerase III promoter required for gammaherpesvirus TMER transcription and microRNA processing, *Gene* 544 (2014) 8–18, <http://dx.doi.org/10.1016/j.gene.2014.04.026>.
- J. Liz, A. Portela, M. Soler, A. Gómez, H. Ling, G. Michlewski, et al., Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region, *Mol. Cell* 55 (2014) 138–147, <http://dx.doi.org/10.1016/j.molcel.2014.05.005>.
- S.A. Melo, M. Esteller, Disruption of microRNA nuclear transport in human cancer, *Semin. Cancer Biol.* 27 (2014) 46–51, <http://dx.doi.org/10.1016/j.semcancer.2014.02.012>.
- J. Winter, S. Jung, S. Keller, R.I. Gregory, S. Diederichs, Many roads to maturity: microRNA biogenesis pathways and their regulation, *Nat. Cell Biol.* 11 (2009) 228–234, <http://dx.doi.org/10.1038/ncb0309-228>.
- C. Matranga, Y. Tomari, C. Shin, D.P. Bartel, P.D. Zamore, Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes, *Cell* 123 (2005) 607–620, <http://dx.doi.org/10.1016/j.cell.2005.08.044>.
- T.A. Rand, S. Petersen, F. Du, X. Wang, Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation, *Cell* 123 (2005) 621–629, <http://dx.doi.org/10.1016/j.cell.2005.10.020>.
- A.K.L. Leung, P.A. Sharp, Quantifying Argonaute proteins in and out of GW/P-bodies: implications in microRNA activities, *Adv. Exp. Med. Biol.* 768 (2013) 165–182, http://dx.doi.org/10.1007/978-1-4614-5107-5_10.
- Y.J. Kim, A. Maizel, X. Chen, Traffic into silence: endomembranes and post-transcriptional RNA silencing, *EMBO J.* 33 (2014) 968–980, <http://dx.doi.org/10.1002/emboj.201387262>.
- J.-S. Yang, E.C. Lai, Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants, *Mol. Cell* 43 (2011) 892–903, <http://dx.doi.org/10.1016/j.molcel.2011.07.024>.
- S. Tomaselli, B. Bonamassa, A. Alisi, V. Nobili, F. Locatelli, A. Gallo, ADAR enzyme and miRNA story: a nucleotide that can make the difference, *Int. J. Mol. Sci.* 14 (2013) 22796–22816, <http://dx.doi.org/10.3390/ijms141122796>.
- M.P. Gantier, C.E. McCoy, I. Rusinova, D. Saulep, D. Wang, D. Xu, et al., Analysis of microRNA turnover in mammalian cells following Dicer1 ablation, *Nucleic Acids Res.* 39 (2011) 5692–5703, <http://dx.doi.org/10.1093/nar/gkr148>.
- Z.S. Kai, A.E. Pasquinelli, MicroRNA assassins: factors that regulate the disappearance of miRNAs, *Nat. Struct. Mol. Biol.* 17 (2010) 5–10, <http://dx.doi.org/10.1038/nsmb.1762>.
- G. Cheng, Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy, *Adv. Drug Deliv. Rev.* (2014) <http://dx.doi.org/10.1016/j.addr.2014.09.001>.
- E.E. Creemers, A.J. Tijssen, Y.M. Pinto, Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circ. Res.* 110 (2012) 483–495, <http://dx.doi.org/10.1161/CIRCRESAHA.111.247452>.
- S. Atay, A.K. Godwin, Tumor-derived exosomes: a message delivery system for tumor progression, *Commun. Integr. Biol.* 7 (2014) <http://dx.doi.org/10.4161/cib.28231>.
- A. Waldenström, G. Ronquist, Role of exosomes in myocardial remodeling, *Circ. Res.* 114 (2014) 315–324, <http://dx.doi.org/10.1161/CIRCRESAHA.114.300584>.
- D.M. Yellon, S.M. Davidson, Exosomes: nanoparticles involved in cardioprotection? *Circ. Res.* 114 (2014) 325–332, <http://dx.doi.org/10.1161/CIRCRESAHA.113.300636>.
- A. Gallo, M. Tandon, I. Alevizos, G.G. Illei, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes, *PLoS One* 7 (2012) e30679, <http://dx.doi.org/10.1371/journal.pone.0030679>.
- A. Turchinovich, L. Weiz, A. Langhein, B. Burwinkel, Characterization of extracellular circulating microRNA, *Nucleic Acids Res.* 39 (2011) 7223–7233, <http://dx.doi.org/10.1093/nar/gkr254>.
- K.C. Vickers, B.T. Palmisano, B.M. Shoucri, R.D. Shamburek, A.T. Remaley, MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins, *Nat. Cell Biol.* 13 (2011) 423–433, <http://dx.doi.org/10.1038/ncb2210>.

- of human pancreatic islets, *Cell Transplant.* 21 (2012) 1305–1320, <http://dx.doi.org/10.3727/096368911X627534>.
- [184] P. Mocharlar, S. Briand, G. Giannotti, C. Dörries, P. Jakob, F. Paneni, et al., AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics, *Blood* 121 (2013) 226–236, <http://dx.doi.org/10.1182/blood-2012-01-407106>.
- [185] L.A. Goldraich, N.C. Martinelli, U. Matte, C. Cohen, M. Andrades, M. Pimentel, et al., Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression, *Biomarkers* 19 (2014) 135–141, <http://dx.doi.org/10.3109/1354750X.2013.870605>.
- [186] F. Olivieri, R. Antonicelli, M. Lorenzi, Y. D'Alessandra, R. Lazzarini, G. Santini, et al., Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction, *Int. J. Cardiol.* 167 (2013) 531–536, <http://dx.doi.org/10.1016/j.ijcard.2012.01.075>.
- [187] C. Widera, S.K. Gupta, J.M. Lorenzen, C. Bang, J. Bauersachs, K. Bethmann, et al., Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome, *J. Mol. Cell. Cardiol.* 51 (2011) 872–875, <http://dx.doi.org/10.1016/j.yjmcc.2011.07.011>.
- [188] I. Eitel, V. Adams, P. Dieterich, G. Fuernau, S. de Waha, S. Desch, et al., Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction, *Am. Heart J.* 164 (2012) 706–714, <http://dx.doi.org/10.1016/j.ahj.2012.08.004>.
- [189] X. Ji, R. Takahashi, Y. Hiura, G. Hirokawa, Y. Fukushima, N. Iwai, Plasma miR-208 as a biomarker of myocardial injury, *Clin. Chem.* 55 (2009) 1944–1949, <http://dx.doi.org/10.1373/clinchem.2009.125310>.
- [190] G.-K. Wang, J.-Q. Zhu, J.-T. Zhang, Q. Li, Y. Li, J. He, et al., Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans, *Eur. Heart J.* 31 (2010) 659–666, <http://dx.doi.org/10.1093/eurheartj/ehq013>.
- [191] W. Aoi, K. Sakuma, Does regulation of skeletal muscle function involve circulating microRNAs? *Front. Physiol.* 5 (2014) 39, <http://dx.doi.org/10.3389/fphys.2014.00039>.
- [192] H. Mizuno, A. Nakamura, Y. Aoki, N. Ito, S. Kishi, K. Yamamoto, et al., Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy, *PLoS One* 6 (2011) e18388, <http://dx.doi.org/10.1371/journal.pone.0018388>.
- [193] T.C. Roberts, C. Godfrey, G. McClorey, P. Vader, D. Briggs, C. Gardiner, et al., Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover, *Nucleic Acids Res.* 41 (2013) 9500–9513, <http://dx.doi.org/10.1093/nar/gkt724>.
- [194] D. Cacchiarelli, I. Legnini, J. Martone, V. Cazzella, A. D'Amico, E. Bertini, et al., miRNAs as serum biomarkers for Duchenne muscular dystrophy, *EMBO Mol. Med.* 3 (2011) 258–265, <http://dx.doi.org/10.1002/emmm.201100133>.
- [195] N. Vignier, F. Amor, P. Fogel, A. Duvallet, J. Poupot, S. Charrier, et al., Distinctive serum miRNA profile in mouse models of striated muscular pathologies, *PLoS One* 8 (2013) e55281, <http://dx.doi.org/10.1371/journal.pone.0055281>.
- [196] J.M. Toivonen, R. Manzano, S. Oliván, P. Zaragoza, A. García-Redondo, R. Osta, MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis, *PLoS One* 9 (2014) e89065, <http://dx.doi.org/10.1371/journal.pone.0089065>.
- [197] A. Donaldson, S.A. Natanek, A. Lewis, W.D.-C. Man, N.S. Hopkinson, M.I. Polkey, et al., Increased skeletal muscle-specific microRNA in the blood of patients with COPD, *Thorax* 68 (2013) 1140–1149, <http://dx.doi.org/10.1136/thoraxjnl-2012-203129>.
- [198] M. Miyachi, K. Tsuchiya, H. Yoshida, S. Yagyu, K. Kikuchi, A. Misawa, et al., Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma, *Biochem. Biophys. Res. Commun.* 400 (2010) 89–93, <http://dx.doi.org/10.1016/j.bbrc.2010.08.015>.
- [199] D.S. Karolina, A. Armugam, S. Tavintharan, M.T.K. Wong, S.C. Lim, C.F. Sum, et al., MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus, *PLoS One* 6 (2011) e22839, <http://dx.doi.org/10.1371/journal.pone.0022839>.
- [200] A.L. Baggish, J. Park, P.-K. Min, S. Isaacs, B.A. Parker, P.D. Thompson, et al., Rapid upregulation and clearance of distinct circulating microRNAs after prolonged aerobic exercise, *J. Appl. Physiol.* 116 (2014) 522–531, <http://dx.doi.org/10.1152/jappphysiol.01141.2013>.
- [201] M. Uhlemann, S. Möbius-Winkler, S. Fikenzer, J. Adam, M. Redlich, S. Möhlenkamp, et al., Circulating microRNA-126 increases after different forms of endurance exercise in healthy adults, *Eur. J. Prev. Cardiol.* 21 (2014) 484–491, <http://dx.doi.org/10.1177/2047487312467902>.
- [202] S. Banzet, M. Chennaoui, O. Girard, S. Racinais, C. Drogou, H. Chalabi, et al., Changes in circulating microRNAs levels with exercise modality, *J. Appl. Physiol.* 115 (2013) 1237–1244, <http://dx.doi.org/10.1152/jappphysiol.00075.2013>.
- [203] T.J. Kirby, J.J. McCarthy, MicroRNAs in skeletal muscle biology and exercise adaptation, *Free Radic. Biol. Med.* 64 (2013) 95–105, <http://dx.doi.org/10.1016/j.freeradbiomed.2013.07.004>.
- [204] G. Giacomazzi, M. Sampaolesi, M. Quattrocelli, Unconventional players on the striated muscle field: microRNAs, signaling pathways and epigenetic regulators, *Curr. Stem Cell Res. Ther.* (2015) <http://www.ncbi.nlm.nih.gov/pubmed/25584907> (accessed February 26, 2015) [Epub ahead of print]; PMID: 25584907.